Extend your brand profile by curating daily news.

Viromed Medical Appoints Christian Strauch to Management Board as Founder Uwe Perbandt Steps Down

By Advos•
Viromed Medical AG has appointed Christian Strauch to its Management Board effective November 16, 2026, as founder Uwe Perbandt resigns for personal reasons, signaling a leadership transition to drive the company's next growth phase in cold plasma technology.
Viromed Medical Appoints Christian Strauch to Management Board as Founder Uwe Perbandt Steps Down

Viromed Medical AG, a Germany-based medical technology company specializing in cold plasma technology, is restructuring its Management Board as it prepares for a new phase of growth. The Supervisory Board has appointed Christian Strauch to the Management Board effective November 16, 2026, for a term lasting until October 31, 2029. Simultaneously, founder Uwe Perbandt has resigned from his position effective December 31, 2026, citing personal reasons.

The leadership change is significant for the company, which has recently achieved market readiness for its cold plasma technology. Dr. Thomas Gutschlag, Chairman of the Supervisory Board, emphasized that the transition occurs by mutual agreement with Perbandt, who shaped Viromed from its inception and developed it into an internationally leading enterprise in cold plasma technology. Gutschlag expressed confidence that Strauch's sales expertise makes him ideal to help shape the next growth phase.

Perbandt reflected on his tenure, stating that he built Viromed with passion and a dedicated team, and expressed pride in the company's achievements. He highlighted the importance of cold plasma technology in helping people and saving lives, and expressed confidence in handing over responsibility to Strauch, whom he described as a highly experienced successor and his preferred candidate.

Christian Strauch brings more than twenty years of experience in building and scaling healthcare companies. As Managing Director of pharmedix GmbH, a Viromed subsidiary since 2024, he has repositioned the company as an omnichannel sales operation. Previously, he built the mail-order pharmacy apo-rot to 450 employees and up to EUR 100 million in annual revenue, and oversaw the sale of its mail-order division to the Zur Rose Group or DocMorris. He also led the integration of acquisitions as Managing Director of two DocMorris subsidiaries, initiated the acquisition of medpex, and restructured the group's procurement. Since 2020, he has been building the Vameda Group and founded two pharmaceutical wholesalers that were sold to an investor group in 2024.

The appointment comes as Viromed, listed on the stock exchange since October 2022, seeks to further advance the use of cold plasma technology in medicine and realize corresponding growth potential. The company distributes innovative cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH, and has a broad customer base in the DACH region and beyond. The leadership transition is expected to support the company's strategic goals and capitalize on the growing market for cold plasma technology. For more information, visit www.viromed-medical-ag.de. The original release is available on www.newmediawire.com.

Advos

Advos

@advos